Regenerative medicine company Cynata Therapeutics has partnered up with the University of New South Wales in a bid to develop a stem cell treatment for coronary artery disease.
Its progress in the biotech space has attracted the attention of the UNSW who have agreed to partner with Cynata using funding secured via the Science Industry Network Seed Fund 2018.
The stem cell company also said it may advance to a phase 2 clinical trial of a new stem cell drug if results of an initial two-stage trial continue to prove the drug’s safety and efficacy.
Furthermore, Cynata reported positive results regarding its phase 1 trial of CYP-001, developed to treat medical complications arising from bone marrow transplants.
CYP Price at posting:
$1.34 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)